![Stephen Biggar](https://cdn.zonebourse.com/static/resize/768/576//static/images/insiders/unknown.png)
Stephen Biggar
Presidente presso ACADIA PHARMACEUTICALS INC.
Patrimonio netto: 95 050 $ in data 31/05/2024
Posizioni attive di Stephen Biggar
Società | Posizione | Inizio | Fine |
---|---|---|---|
ACADIA PHARMACEUTICALS INC. | Independent Dir/Board Member | 22/01/2013 | - |
Presidente | 10/06/2016 | - | |
Direttore/Membro del Consiglio | 22/01/2013 | 10/06/2016 | |
KINIKSA PHARMACEUTICALS INTERNATIONAL, PLC | Direttore/Membro del Consiglio | 01/10/2015 | - |
Independent Dir/Board Member | 01/10/2015 | - | |
TSCAN THERAPEUTICS, INC. | Independent Dir/Board Member | 01/03/2021 | - |
Presidente | 12/06/2024 | - | |
Direttore/Membro del Consiglio | 01/03/2021 | 12/06/2024 | |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Direttore/Membro del Consiglio | - | - |
Storia della carriera di Stephen Biggar
Precedenti posizioni note di Stephen Biggar
Società | Posizione | Inizio | Fine |
---|---|---|---|
SYNAGEVA BIOPHARMA CORP | Direttore/Membro del Consiglio | 02/11/2011 | 22/06/2015 |
Independent Dir/Board Member | 02/11/2011 | 22/06/2015 | |
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Direttore/Membro del Consiglio | - | 04/11/2011 |
BIOCRYST PHARMACEUTICALS, INC. | Direttore/Membro del Consiglio | 03/10/2005 | 10/10/2011 |
Vivelix Pharmaceuticals, Ltd.
![]() Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Direttore/Membro del Consiglio | - | - |
Baker Bros. Advisors LP
![]() Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Gestore di Portafoglio-Azioni | 01/04/2000 | - |
Corporate Officer/Principal | 01/04/2000 | - |
Formazione di Stephen Biggar
Rochester Christian University | Undergraduate Degree |
Stanford University | Doctorate Degree |
Statistiche
Distribuzione geografica
Stati Uniti | 10 |
Bermuda | 2 |
Canada | 2 |
Posizioni
Director/Board Member | 10 |
Independent Dir/Board Member | 4 |
Chairman | 2 |
Settori
Health Technology | 9 |
Consumer Services | 3 |
Finance | 2 |
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Società collegate
Società quotate in Borsa | 3 |
---|---|
BIOCRYST PHARMACEUTICALS, INC. | Health Technology |
ACADIA PHARMACEUTICALS INC. | Health Technology |
TSCAN THERAPEUTICS, INC. | Health Technology |
Aziende private | 6 |
---|---|
Baker Bros. Advisors LP
![]() Baker Bros. Advisors LP Investment ManagersFinance Baker Bros. Advisors LP (BBA) is an independent, SEC-registered investment advisor and hedge fund manager headquartered in New York City. The firm was founded by Julian Baker and Felix Baker in 2000 and do-business-as Baker Brothers Investments. BBA serves as a discretionary investment advisor to pooled investment vehicles operating as private investment funds and to a managed account. | Finance |
Synageva BioPharma Corp. /Old/
![]() Synageva BioPharma Corp. /Old/ BiotechnologyHealth Technology Synageva BioPharma's ultimate goal is to improve patient lives by providing access to breakthrough novel, next generation (i.e. significantly improved), and certain follow on protein therapeutics. Synageva's proprietary platform technologies, including SEP™, provide a number of sustainable competitive advantages for developing and commercializing these therapeutics including: high expression levels, more efficient purification processes, significantly reduced costs of production, rapid scalability, and consistency of end product. Its platform has already demonstrated its ability to produce a wide array of human therapeutic proteins including monoclonal antibodies (mAbs), cytokines, and other biotherapeutics. It has multiple compounds in development, including 2 monoclonal antibodies with enhanced ADCC activity, novel therapeutic proteins, and several cytokines including one with unique efficacy advantages. The commercialization strategy for these product candidates is designed to maximize its ability to rapidly develop and bring them to market so that they can address patients' unmet medical needs. The key elements of the strategy are to: 1. Establish partnerships to co-develop and commercialize select product candidates in large specialty markets 2. Independently develop and commercialize select novel product candidates that target high value orphan specialty markets 3. Establish partnerships to express proteins from other companies wanting to leverage the unique glycosylation advantages and other characteristics of the SEP™. | Health Technology |
Synageva BioPharma Corp.
![]() Synageva BioPharma Corp. BiotechnologyHealth Technology Synageva BioPharma Corp. is a biopharmaceutical company which focuses on the discovery, development, and commercialization of therapeutic products for patients with life-threatening rare diseases and high unmet medical need. The company is currently evaluating sebelipase alfa in global clinical trials for LAL Deficiency, a lysosomal storage disease associated with liver damage and accelerated atherosclerosis in children and adults, and in infants, premature death often before six months of age. Synageva BioPharma was founded in 1993 and is headquartered in Lexington, MA. | Health Technology |
Kiniksa Pharmaceuticals Ltd.
![]() Kiniksa Pharmaceuticals Ltd. Pharmaceuticals: MajorHealth Technology Kiniksa Pharmaceuticals International Plc is a biopharmaceutical company, which engages in discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical need. Its products include Rilonacept, Mavrilimumab, Vixarelimab, and KPL-404. The company was founded by Sanj K. Patel, Stephen Frank Mahoney, Krisha S. Mahoney, Thomas W. Beetham, Christopher Heberlig, Carsten Boess, Rasmus Holm-Jorgensen, Gregory Alex Grabowksi, Aaron Isadore Young, Eben P. Tessari, Jennifer Lynne Mason and Mickenzie Elizabeth Gallagher in July 2015 and is headquartered in Lexington, MA. | Health Technology |
Vivelix Pharmaceuticals, Ltd.
![]() Vivelix Pharmaceuticals, Ltd. Pharmaceuticals: MajorHealth Technology Vivelix Pharmaceuticals, Ltd. manufactures and sells pharmaceutical products. The private company is based in Hamilton, BM. and has subsidiaries in the United States. The Bermudian company was founded by William P. Forbes. | Health Technology |
Notch Therapeutics, Inc.
![]() Notch Therapeutics, Inc. Pharmaceuticals: OtherHealth Technology Notch Therapeutics, Inc. engages in the development of cell therapies for the treatment of diseases. It offers technology platform, which uses genetically tailored stem cells as a renewable source for creating allogeneic T cell therapies that expand treatment options and deliver cell immunotherapies to patients. The company was founded by Juan Carlos Zuniga-Pflucker and Peter Zandstra in 2018 and is headquartered in Toronto, Canada. | Health Technology |
- Borsa valori
- Insiders
- Stephen Biggar
- Esperienza